Incyte Corporation (Incyte) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs. Its advanced compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor, LY3009104 (INCB28050), which is subject to a collaboration agreement with Eli Lilly and Company in which Lilly received worldwide development and commercialization rights for the compound for inflammatory and autoimmune diseases. In November 2011, JAKAFI became commercially available in the United States and is being marketed in the United States.
Route 141 & Henry Clay Rd.
WILMINGTON, DE, United States 19880
|Independent Chairman of the Board||Richard De Schutter|
|President, Chief Executive Officer, Director||Paul Friedman|
|Chief Financial Officer, Executive Vice President||David Hastings|
|Executive Vice President, General Counsel||Eric Siegel|
|Executive Vice President - Human Resources||Paula Swain|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||135.7M||Book Value||$-1.31|
|Annual Dividend Rate||$0.00||Price/Sales (TTM)||8.6|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||179.6x|
|Pay Date||1/1/01||Operating Margin||9.41%|
*GAAP = prior to non-GAAP analyst adjusted earnings.